Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record.

NONAMYLOIDOTIC MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE

Open access
Buxbaum, Joel, Gallo, Gloria·1999·Hematology/Oncology Clinics of North America

Abstract

B-cell proliferative disorders may display their pathogenic effects by increased cell numbers, increased concentrations of the molecules produced by those cells, or both. Immunoglobulins, a major secretory product of terminally differentiated B cells, are the mediators of specific forms of tissue pathology seen in multiple myeloma, occult plasma cell dyscrasias, Waldenström's disease, and chronic lymphocytic leukemia. Intact monoclonal immunoglobulins, by virtue of their properties as antibodies, can have autospecificity with either immune complex or direct tissue damage. They can also self-aggregate to produce syndromes associated with hyperviscosity. When only light chains are produced, or when the light chains produced are greater than the amount of heavy chain synthesized by the expanded clone, or, less commonly, when some forms of truncated heavy chain are secreted, three forms of tissue damage have been described. All have the kidney as a major target organ.45 In myeloma kidney light chains become insoluble in the renal tubular lumen, forming dense casts (Bence Jones cast nephropathy [BJCN]). Its occurrence is a function of both plasma cell load and the physicochemical properties of the specific light chain, requiring both large amounts of the protein and a tendency to aggregate under the conditions of concentration and pH achievable in the human nephron. The property appears to be independent of light-chain class. In primary amyloidosis (AL) and heavy-chain amyloidosis (AH) light chains or their fragments (most commonly of the λ class) or truncated heavy chains form fibrillar, Congo red–binding deposits in many tissues which ultimately result in organ compromise. The more recently recognized form of light-chain deposition, light-chain deposition disease (LCDD), is characterized by deposition of non-Congophilic material which appears amorphous with conventional histologic methods. It is detected by its reactivity with specific anti-immunoglobulin light-chain (usually anti κ) antisera.41 The original definition of immunoglobulin light chains as the precursor of both amyloid and LCDD forms of tissue deposition has been expanded with the recognition that some heavy chains with domain deletions can produce amyloidosis (designated as AH) and that the non-Congophilic tissue deposits may be comprised of immunoglobulin heavy-chain fragments as a major component (light-and-heavy-chain deposition disease [LHCDD]) or as a sole component (heavy-chain deposition disease [HCDD]). To encompass all the identified forms of monoclonal immunoglobulin-related tissue deposition under a single rubric, the designation monoclonal immunoglobulin deposition disease (MIDD) has been suggested,3 with AL, AH, LCDD, LHCDD and HCDD as subtypes, and with the deposits further defined on the basis of the class of immunoglobulin polypeptide involved and its ultrastructure. It has been argued that, if the basic mechanisms governing tissue deposition in amyloid and nonamyloid MIDD (NAMIDD) are different, grouping them together is inappropriate.40 If, however, the two forms of deposits represent different aspects of the same pathogenetic process resulting from the production of the same protein during the course of a monoclonal B-cell expansion, such a classification is appropriate. At present, the issue is unsettled, although the authors believe that current data favor a unimodal process with variations. Primary amyloidosis and LCDD appear to be more dependent than myeloma kidney on the particular structure of the light chain, because AL and LCDD occur both in the presence and in the absence of clinical myeloma.2 In autopsy and in clinical series of consecutive patients with multiple myeloma, 11% to 20% of patients display tissue amyloid deposition.25, 31, 35 Conversely, data from many centers indicate that only 20% of all AL patients have myeloma at the time of presentation.31 Although there are fewer studies in which the incidence of LCDD in myeloma has been determined, the best estimates indicate that 5% to 10% of myeloma patients have LCDD.25, 35 Review of the first 150 reported cases of well-documented NAMIDD suggests that myeloma was present in 50% to 60% of the cases; however, in many of these cases, the criteria used to establish the diagnosis of myeloma were not clearly stated.4 It is possible that more limited forms of plasma cell dyscrasia, not fulfilling all the requirements for myeloma, were included. For example, studies from French investigators revealed that 20 of 26 patients were diagnosed as having myeloma at the time of presentation or developed the requisite diagnostic features over the 2-year period following recognition of the tissue deposits.6 The latter observation suggests that some of these patients could have been classified as having smoldering myeloma.32 Among the LCDD patients identified by renal biopsy and treated by the authors, 6 of 24 (25%) had a confirmed diagnosis of myeloma with nodular infiltrates in

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0889-8588(05)70123-4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 174

Metadata

Authors
Buxbaum, J., & Gallo, G.
Venue
Hematology/Oncology Clinics of North America
Publisher
Elsevier BV
Published
1999-12
Volume
13
Issue
6
Pages
1235-1248
ISSN
0889-8588 (ISSN-L)
OpenAlex
W2064309041
Cited by
174
References
0
FWCI
2.00
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NONAMYLOIDOTIC MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE. https://app.cochat.ai/papers/10.1016/s0889-8588(05)70123-4
The paper
Buxbaum, J., & Gallo, G. (1999). NONAMYLOIDOTIC MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE. Hematology/Oncology Clinics of North America. https://doi.org/10.1016/s0889-8588(05)70123-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.